AbCellera Biologics (ABCL) closed at $11.93 on Oct 19, 2026, up 1.1% on the day. The stock is down 5.5% over the past month, up 99.8% over three months, up 248.8% year to date and up 104.3% over the past year. It trades 20.5% below its 52-week high of $15.02 and 334.6% above its 52-week low of $2.74. The close sits below its 50-day moving average ($12.02) and above its 200-day moving average ($6.48).
NextPick tracks ABCL in its AI Drug Discovery basket alongside TEM, RXRX, SDGR, CERT and ABSI. As of Oct 19, 2026, the basket's money-flow score is -38 (outflow), and the basket is down 6.9% over five sessions. Over the past month ABCL ranks 2nd of 6 basket members by price change.
Form 4 filings over the last 90 days show 4 open-market purchases and no open-market sales by insiders.
Yes — the Oct 19, 2026 close of $11.93 is 84.1% above the 200-day average of $6.48.
ABCL closed 20.5% below its 52-week high of $15.02.
NextPick groups ABCL with TEM, RXRX, SDGR, CERT and ABSI in its AI Drug Discovery basket.
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
